Aaron Johnson is the Vice President of Marketing & Customer Strategy and a part of the technical sales team at Accumold. He is recognized as a leader on the subject on micro injection molding and has developed and presented numerous technical presentations and has been published in many industry trade publications. He has been with Accumold since 2005 and currently finishing his Master's in Business Administration.
Amber is an entrepreneur with a broad variety of skills with 24 years experience. She has led 3 previous business to successful exits. She is an out of the box thinker, can do and go for it mentality. Amber is the inventor of EPIWatch and owner of the concept patent and the mechanical patent.
Andreas is currently Senior Technical Manager and in this role, he supports external manufacturing sites producing for Novartis. He has 25 years of pharmaceutical experience in different roles within parenteral drug product manufacturing.
He joined Novartis 2014 for implementation of a pre-filled syringe line as Production Manager for pre-filled syringes covering Compounding, Filling and Visual Inspection. Prior to Novartis, Andreas worked at Fresenius Kabi as single point of contact for pre-filled syringes and as manager of a QC lab.
As a Sales Director Ashley works with global pharma customers in to engineer efficient yet highly flexible packaging lines for Parenterals.
Modularity is essential to meet the technical requirements of the growing diversity of Pre-filled Syringe and Injection Device types. Operational and commercial viability is achieved through a quality driven package solution approach.
Asmita Khanolkar has a Master’s degree in Materials Science & Engineering from Worcester Polytechnic Institute in Worcester, MA, USA. With over 25 years of manufacturing experience specializing in the Medical Device and Pharmaceutical industry, she has managed various device projects from concept to commercial launch.
Dr. Bassil Akra is CEO and Owner of AKRA TEAM GmbH, a consultancy company which was founded in 2021 to support the various stakeholders in the healthcare system achieving their target in a highly regulated business area. He spent the last year consulting and supporting medical device, in-vitro diagnostic, combination device companies preparing their strategy for the EU regulations MDR 2017/745 and IVDR 2017/746.
After studying Chemical Engineering Beate Treffler joined Hoechst/Clariant's Plastic Additives division already 30 years ago. After holding various positions in Technical Service, Development and Marketing, Beate took over the lead of the dedicated Healthcare Polymers Solutions team in 2015 which focuses on enhancing and protecting healthcare products.
Dr. Clemens Günther received his diploma in biology and doctorate for natural sciences from the Free University, Berlin-Germany. Dr. Günther has gained over 30 years experience in drug development. He has been involved in nonclinical development and regulatory toxicology of small molecules, biologics, medical devices and drug device combination products.
As VP at Fresenius Kabi, Dr. Franz Kainz is heading the contract manufacturing services for sterile pharmaceuticals and medical devices with an annual three-digit million Euro budget building up on 10+ years of management experience at two multi-billion euro companies. As a scientist by training, Franz obtained a PhD in Developmental Genetics at the University of Cambridge followed by postdoctoral research at Harvard University.
Holger Krenz, Vice President Applications Development Europe, at SiO2 Material Science, is together with his team responsible for the European customer activities to support the commercialization of SiO2´s product portfolio. He is a biologist with a focus on Neurophysiology working for the last 20 years in the medical device and pharmaceutical packaging industry.
Jakob is an Engineer and Materials Scientist by training with an MSc degree in Chemical Engineering from the Royal Institute of Technology in Stockholm, Sweden and a PhD in Polymer Science from the Swiss Federal Institute of Technology in Lausanne, Switzerland. He has written and published close to 40 peer-reviewed papers on medical devices, packaging materials and polymers and is a regular contributor to technical and scientific conferences.
Dr Joël Richard is currently Chief Development Officer at MedinCell (Montpellier, France). He is leading all the drug development activities of the company, based on the proprietary technology BEPO® for Long-Acting Injectables. (LAIs). These activities comprise formulation and process development, device development, analytical development, process transfer and scale-up, manufacturing and supply of clinical batches, regulatory affairs, non-clinical and clinical development operations, quality and regulatory compliance.
Raphael has over 20 years of pharmaceutical industry experience. He has a Ph.D. in organic chemistry from the Weizmann Institute of Science in Israel, a post-doctorate at the US Air Force Research Lab in Aberdeen Proving Ground, Maryland, and another post-doctorate at Duke University Medical Center, North Carolina. In 2001 he joined a startup biotech company in Israel that performed rational drug design by molecular modeling, and in 2003 Raphael joined the Medicinal Chemistry department at Teva Pharmaceuticals.
ené Holm received his pharmaceutical training at the Royal Danish School of Pharmacy, now the school of pharmacy at University of Copenhagen, Denmark, in 1998 and his PhD in biopharmaceutics from the same institution in 2002. Dr. Holm joined Lundbeck in 2001 and changed to Janssen in 2016. Dr. Holm has worked within pharmaceutical development, formulations for non-clinical testing in drug discovery, physical chemistry and material science covering both small and large molecules and is now responsible for the functional unit ensuring development of all non-solid formulations for Janssens small molecule value stream.
Tudor Arvinte, Ph.D., received his academic training in physics at the University of Jassy, Romania, and his Ph.D. in biophysics from the University of Düsseldorf, Germany. He performed his doctoral work and postdoctoral stage at the Max-Planck-Institute West Germany and held numerous research positions in Europe and the USA: at C.N.R.S., Orléans, France, at Cornell University, New York, at Texas A&M University, and at the Biophor Corporation, College Station, Texas, USA.